121 related articles for article (PubMed ID: 9740693)
21. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
22. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
23. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Noda K; Tanaka K; Ozaki M; Hirabayasi K; Hasegawa K; Nishiya I; Yakushiji M; Izumi R; Tomoda Y; Ogita Y; Sugimori H; Yamabe T; Kudo R; Yajima A; Terashima Y; Fujii S; Suzuoki Y; Okada H; Kono I; Ochiai K; Yamamoto T; Ikeda M; Umesaki N; Saito T; Niitani H
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2061-8. PubMed ID: 9838908
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
25. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Buller RE; Mannel RS; Webster KD
Gynecol Oncol; 2003 May; 89(2):267-70. PubMed ID: 12713990
[TBL] [Abstract][Full Text] [Related]
26. [Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group].
Ikeda M; Noda K; Hiura M; Tamaya T; Ozaki M; Hatae M; Ozawa M; Yamabe T; Tanaka K; Izumi R; Okada H; Ogita Y; Hoshiai H
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2249-57. PubMed ID: 9881082
[TBL] [Abstract][Full Text] [Related]
27. [CDDP-resistant early recurrent uterine cervical cancer successfully treated with low-dose oral etoposide: a case report].
Beppu M; Hiura M; Nogawa T; Kawakami Y; Yokoyama T; Chiba T
Gan To Kagaku Ryoho; 1998 May; 25(6):933-6. PubMed ID: 9617335
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
30. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
Wagenaar HC; Colombo N; Vergote I; Hoctin-Boes G; Zanetta G; Pecorelli S; Lacave AJ; van Hoesel Q; Cervantes A; Bolis G; Namer M; Lhommé C; Guastalla JP; Nooij MA; Poveda A; Scotto di Palumbo V; Vermorken JB
Gynecol Oncol; 2001 Jun; 81(3):348-54. PubMed ID: 11371121
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
32. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
33. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix--final results of a prospective phase II-study.
Vrdoljak E; Omrcen T; Novaković ZS; Jelavić TB; Prskalo T; Hrepić D; Hamm W
Gynecol Oncol; 2006 Nov; 103(2):494-9. PubMed ID: 16814371
[TBL] [Abstract][Full Text] [Related]
34. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
35. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
36. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Rose PG; Markman M; Bell JG; Fusco NL
Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
[TBL] [Abstract][Full Text] [Related]
37. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
Umesaki N; Izumi R; Fushiki H; Hasegawa K; Kono I; Nishida M; Noguchi H; Okuda H; Sugimori H; Takizawa K; Udagawa Y; Yamamoto K; Tanaka T; Noda K
Gynecol Oncol; 1999 Oct; 75(1):142-4. PubMed ID: 10502441
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
Fowler JM; Blessing JA; Burger RA; Malfetano JH
Gynecol Oncol; 2002 May; 85(2):311-4. PubMed ID: 11972393
[TBL] [Abstract][Full Text] [Related]
39. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
Bookman MA; Blessing JA; Hanjani P; Herzog TJ; Andersen WA
Gynecol Oncol; 2000 Jun; 77(3):446-9. PubMed ID: 10831357
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of menogaril in patients with squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Barrett RJ; Gallup DG
Gynecol Oncol; 1994 Feb; 52(2):229-31. PubMed ID: 8314144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]